Revaprazan

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
01220102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern… (More)
Is this relevant?
2012
2012
Chronic gastric inflammation developing after Helicobacter pylori (H. pylori) infection is responsible for either dyspeptic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
BACKGROUND To date, no definitive treatment of functional dyspepsia (FD) has been proven to be effective and reasonably well… (More)
  • figure 1
  • table II
  • figure 2
  • table III
  • table IV
Is this relevant?
2011
2011
Revaprazan is the first acid pump antagonist with a function similar to that of proton pump inhibitors (PPIs). It has a dual… (More)
Is this relevant?
2011
2011
BACKGROUND/AIMS Revaprazan (Revanex(R)) is a novel proton pump inhibitor (PPI) that has a somewhat different effect on proton… (More)
Is this relevant?
2010
2010
BACKGROUND AND AIM Revaprazan is a novel acid pump antagonist. The aim of this study was to investigate the inhibitory effect of… (More)
Is this relevant?
Review
2010
Review
2010
BACKGROUND/AIMS Revaprazan, a novel acid-pump antagonist, and proton-pump inhibitors (PPIs) have pH-independent effects on ulcer… (More)
Is this relevant?